Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Prostate cancer is one of the most common cancers that occur in men. While it can be life-threatening, the disease is treatable, and the earlier it is detected, the better the treatment outcome.

For decades, it has been known that prostate specific antigen ‒ or PSA ‒ tests are a flawed way to diagnose prostate cancer. Many men have a high PSA without having cancer. Others have low PSA that ...

Screening PSA levels at aged 65-69 may inform the decision to continue or discontinue prostate cancer screening after age 70 years, regardless of patient race and ethnicity. The absolute risks of ...

The rate at which PSA rises after hormonal therapy for prostate cancer is a key factor in determining the effectiveness of the treatment. For patients with recurrent and advanced prostate cancer, ...

Some men may be candidates for more prolonged PSA testing intervals. High PSA and short PSA double time are associated with a greater likelihood of a positive bone scan. PSA levels and kinetics may be ...